Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

By J. Dixon, P. Bhathal, P. O’Brien. Gastroenterology, 2001

1,399 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/bc187f5c9351e7c7a9b762db83bf39312fd18c1d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. C. Day
4. S. Friedman
5. J. Clark
6. K. Cusi
7. Asociacion Latinoamericana para el Estudio del Higado
8. A. Sanyal

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. S. Friedman
6. J. Clark
7. E. Brunt
8. C. Day

In Pathology and Forensic Medicine

1. J. Clark
2. A. Sanyal
3. M. Rinella
4. K. Cusi
5. E. Brunt
6. Asociacion Latinoamericana para el Estudio del Higado
7. S. Harrison
8. S. Bellentani

Citations in the corpus

• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “NAFLD patients with metabolic syndrome and those with type 2 diabetes mellitus, had been shown to be at increased risk of having liver fibrosis in both Western and Asian cohorts [220,225].”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “In bariatric surgery patients NASH is characterized by isolated portal fibrosis and azonal steatosis [42,133,137].”
• Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss (2004, methodology): “*There are two scores for cellular injury, (1) Mallory bodies and (2) ballooning degeneration, that were scored independently.”
• The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults (2006, result): “Dixon et al had slightly different findings in their study of 105 patients undergoing bariatric surgery.(37) In this group, they found that hypertension, ALT .”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “Although several cross-sectional studies (210-216) have suggested a beneficial effect of light alcohol consumption (on average less than 1 drink per day) on the presence (defined either biochemically or by imaging) and severity of NAFLD, a recent meta-regression analysis of 42,059 participants combi”
• Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. (2010, background): “2000), 50 80% in the obese population (Farrell and Larter 2006) and 86 96% in severely obese patients (Dixon et al. 2001; Gholam et al. 2007).”
• Non-alcoholic fatty liver disease: the mist gradually clears. (2008, background): “With respect to alcohol intake, while there is no doubt that obesity increases risk of cirrhosis in heavy drinkers [25] emerging evidence suggests that ‘‘sensible” light alcohol intake may be protective versus NAFLD/ NASH [26,27], an effect that appears likely to be due to the beneficial effect of l”